Catalent boosts cold chain packaging services
Will welcome seven temperature-controlled processing suites to accommodate various biologic drug needs
Catalent, a contract development and manufacturing organization (CDMO), has increased cold chain packaging capabilities at its 200,000 square-foot Philadelphia facility to support increased demand for the distribution of biologic drugs, along with advanced cell and gene therapies.
Work is now underway at the facility to grow the packaging area by about 20,000 square feet, and includes the addition of seven new temperature-controlled processing suites, which can operate at either refrigerated or frozen conditions to meet the requirements of the drugs being handled. Additional ambient space has also been added for packaging operations and materials storage.
The new suites feature full serialization capabilities that are designed for small-scale batches of commercial products. Validation of the equipment is expected to be completed by the end of Q1 2022.
“Advanced therapeutics require increasingly complex handling requirements, and the investment we have made in Philadelphia allows Catalent to operate efficient packaging processes and operations, bridging the gap between clinical scale and niche commercial volumes,” comments Ann McMahon, general manager of commercial & integrated development operations at Catalent Clinical Supply Services.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
